Publications

Abstracts

Real-world outcomes of patients with resected stage IIIA melanoma treated with adjuvant nivolumab

Outcomes of nivolumab (NIVO)-treated patients (pts) with advanced non-small cell lung cancer (aNSCLC) in United States community oncology practice.

Use of an electronic health record (iKnowMed), in conjunction with evidence-based pathways, for data capture and outcome measurement in colorectal cancer patients treated with first-line therapy in the US Oncology Network

A real-world comparative analysis of pomalidomide (POM) and other antimyeloma treatments following lenalidomide (LEN) discontinuation among patients with multiple myeloma

Early physician spillover responses to the oncology care model

EARLY real-world treatment and dosing patterns of ribociclib for metastatic breast cancer (mBC): a retrospective observational study

Overall survival (OS) in advanced non-small cell lung cancer (aNSCLC) patients treated with frontline chemotherapy or immunotherapy by comorbidity: A real-world data (RWD) collaboration

Real-world (RW) systemic treatment patterns and clinical outcomes in locally advanced (LA) and recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC) patients (PTS)

Real-world clinical outcomes in avelumab-treated patients (pts) in the United States (U.S.) from SPEAR-Merkel Study informing treatment Pathway decisions in Merkel cell carcinoma (MCC)

Risk of recurrence in patients with HER2+ breast cancer who achieved a pathological complete response (pCR) after neoadjuvant pertuzumab and trastuzumab (nPT), and received adjuvant trastuzumab (aT): Real-world evidence

Treatment outcomes and healthcare resources utilization (HRU) among patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy in US community oncology setting

Trends in immunotherapy use in patients with advanced non-small cell lung cancer (aNSCLC): Analysis of real-world data

Real-world outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) who received first- or second-line immunotherapies (IO) in the United States (US).

Concordance of real-world time-to-event endpoints with clinical outcomes in oncology studies

Concordance of death date assessments between the Social Security Death Master File and electronic health records in a US community oncology setting

Drivers of new drug adoption in oncology

Outcomes of nivolumab (NIVO)-treated patients (pts) with advanced non-small cell lung cancer (aNSCLC) in United States community oncology practice.

Treatment patterns among patients with EGFRm NSCLC treated in the US community oncology setting

ALK inhibitor sequencing and outcomes among ALK-positive (ALK+) non-small cell lung cancer (NSCLC) patients in the US community oncology setting

Treatment Patterns and Outcomes of Advanced Malignant Pleural Mesothelioma (MPM) Patients in a Community Practice Setting

Treatment patterns and outcomes among patients with advanced cutaneous squamous cell carcinoma (CSCC) in a US community oncology setting

Real-world outcomes of metastatic urothelial carcinoma (mUC) patients (pts) treated with first or second-line immunotherapies (IO) in the United States (US)

Real-world patient profiles and clinical outcomes among patients with BRAF-positive advanced melanoma treated with first-line anti-PD1 monotherapies or BRAF+MEK inhibitor combination therapy in the United States (US) community oncology setting

Development of Playbook for chart review in real-world data

Impact of EHR technology updates on patients’ access to oncology drugs

Retrospective Real-World Assessment of Response Outcomes in Oncology

SPEAR-Bladder (Study informing treatment Pathway dEcision in bladder cAnceR): Influence of treatment sequencing on time to treatment failure and overall survival in the United States

Treatment Patterns and Outcomes of 159 Ibrutinib-Treated MCL Patients in the US: A Retrospective Electronic Medical Record Database and Chart Review Study

Outcomes among patients with EGFR-mutant metastatic NSCLC with and without brain metastases

Patient profiles and treatment patterns among patients with advanced melanoma treated in the US community oncology setting: A retrospective, observational study

Real-world treatment patterns among advanced soft tissue sarcoma patients receiving systemic therapy in a community oncology setting in the United States

Patient characteristics and treatment patterns from SPEAR-BLADDER: Study informing treatment Pathway decision in bladder cancer

Adjuvant therapy utilization among stage III melanoma patients

SPEAR-Bladder (Study informing treatment Pathway dEcision in bladder cAnceR): first- through third-line time to treatment failure in the US

Safety of Split First Dosing vs Standard Dosing Administration of Daratumumab among Multiple Myeloma Patients Treated in a US Community Oncology Setting: A Real-World Observational Study

Treatment Patterns and Outcomes of 159 Ibrutinib-Treated MCL Patients in the United States: A Retrospective Electronic Medical Record Database and Chart Review Study

Real world utilization and outcomes of pembrolizumab for the treatment of patients with advanced melanoma in US community oncology practice

Chemotherapy costs, but not resource utilization, are inversely correlated with the primary platinum-free interval among outpatients with recurrent ovarian cancer

Treatment outcomes with first-line (1L) nab-Paclitaxel + gemcitabine (AG) and FOLFIRINOX (FFX) in metastatic pancreatic adenocarcinoma ASCO

An Observational Study of Patients with Advanced Melanoma Receiving Pembrolizumab in Real World US Community Oncology Practice

Understanding treatment patterns and outcomes in patients with metastatic NSCLC treated in a US Community oncology network

Treatment patterns in recurrent/metastatic head and neck squamous cell carcinoma in the US

Real-world treatment patterns of adult multiple myeloma patients treated with carfilzomib in the US community oncology setting

Real world treatment utilization and outcomes of patients with metastatic bladder cancer by cisplatin eligibility in US community oncology practice

Carfilzomib Dosing Patterns and Time to Next Treatment Among Adult Patients with Multiple Myeloma Treated in the US Community Oncology Setting

A Real-World Comparative Analysis of Carfilzomib and Other Systemic Multiple Myeloma Chemotherapies in the US Community Oncology Setting

Understanding Ibrutinib Treatment Discontinuation Patterns for Chronic Lymphocytic Leukemia

MCL Treatment Patterns and Outcomes: A Community Oncology Practice Experience

Clinical Profiles, Treatment Characteristics and Outcomes among Newly Diagnosed Hodgkin lymphoma Patients Presenting with Unfavorable and Advanced Disease within a US Community Oncology Setting

Second-line treatment patterns and outcomes of metastatic bladder cancer patients in clinical practice

Predictive factors associated with ramucirumab monotherapy or combination therapy among patients with gastric/gastroesophageal junction cancer in the community oncology setting

Treatment patterns, clinical outcomes, and health care resource utilization in patients with metastatic gastroenteropancreatic neuroendocrine tumors (mGEP-NETs)

Real-world outcomes of patients with metastatic merkel cell carcinoma treated with second-line or later chemotherapy in a community oncology setting in the United States

Treatment patterns and clinical outcomes in pazopanib compared to sunitinib as first line therapy for patients with advanced/metastatic renal cell carcinoma (aRCC) in a US community oncology setting

Sustained impact of primary platinum-free interval and BRCA1/2 mutation status on survival in patients with ovarian cancer after multiple lines of therapy

Real-world use of first-line chemotherapy in post-menopausal patients with HR-positive HER2-negative metastatic breast cancer (mBC) in a US community oncology network

Early treatment utilization of palbociclib for metastatic breast cancer (MBC) in a U.S. community oncology network

Treatment patterns and clinical outcomes of patients with metastatic gastroenteropancreatic neuroendocrine tumors (mGEP-NETs)

Comparative effectiveness of pazopanib and sunitinib as first line therapy for patients with advanced/metastatic renal cell carcinoma in a US community oncology setting

Axitinib treatment among patients with mRCC in a U.S. community oncology setting: A retrospective study of 135 patients

Real world treatment patterns and outcomes in HER2 positive MBC patients with brain metastasis in the US community oncology setting

Management of elderly patients with diffuse large B-cell lymphoma in a network of community oncology practices in the United States

Clinical characteristics, treatment patterns, and outcomes for patients with HER2-positive metastatic breast cancer treated with pertuzumab in the first-line in a real-world setting

Carfilzomib dosing patterns and survival in patients with relapsed and refractory multiple myeloma: an analysis from US community oncology practices

Pertuzumab (P) use in first-line HER2-positive metastatic breast cancer (mBC) in US community oncology practices: Treatment patterns and outcomes

Outcomes of advanced renal cell carcinoma patients (aRCC) treated with mammalian target of rapamycin inhibitor (mTORi) therapy following first-line pazopanib (PAZ) in a US Community Oncology Setting

Outcomes of advanced renal cell carcinoma patients (aRCC) treated with first-line pazopanib (PAZ) in a US community oncology setting

Treatment patterns and outcomes in metastatic colorectal cancer (mCRC) patients treated in a community oncology setting

Bridging to survivorship in breast cancer: How BMI weighs in

Real-world safety and efficacy of nab-paclitaxel in patients with metastatic breast cancer (mBC) treated in the united states: results from a health insurance database

Treatment of patients (pts) with HER2- metastatic breast cancer (MBC) with nab-paclitaxel (nab-P) in the clinical practice setting—Results of a US Oncology survey

Impact of pathways on chemotherapy administration before death

Bridging to survivorship in breast cancer: Learning how treatment impacts mental health among early-stage breast cancer survivors

Types, frequency, and adherence of molecular tests in chronic myelogenous leukemia at chronic phase (CML-CP) in the U.S. community setting

Treatment patterns, biomarker testing, and outcomes in patients with nonsquamous non-small cell lung cancer (NSCLC) receiving second-line treatment in the US Oncology network

Evaluation of survival outcomes in select first-line treatment regimens for advanced nonsquamous non-small cell lung cancer patients

Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC)

Relative dose intensity of taxane-based chemotherapy in patients with stage IV breast cancer

Retrospective analysis of long-term survivors with HER2+ metastatic breast cancer (MBC) treated with trastuzumab in a community setting

Dose delays, dose reductions, and relative dose intensity in early stage breast cancer patients receiving (neo)adjuvant chemotherapy in community oncology practices

Association between treatment adherence and response among patients with chronic myeloid leukemia (CML) receiving first-line TKIs in the community setting

Comparable outcomes with bortezomib-cyclophosphamide-dexamethasone (VCD) and bortezomib-lenalidomide-dexamethasone (VRD) for initial treatment of newly diagnosed multiple myeloma (MM)

Impact of route of bortezomib (B) administration on dose intensity and time to dose reduction in previously untreated patients (pts) With multiple myeloma (MM)

Retrospective data study evaluating resource utilization among metastatic renal cell carcinoma patients receiving oral versus intravenous mTOR inhibitors

Treatment practice patterns and survival among patients with metastatic soft tissue sarcoma (mSTS) in a community setting in the United States

Sunitinib dosing, toxicity, and outcomes in first-line advanced renal cell carcinoma (aRCC): A U.S. Oncology Network (USON) retrospective study

Retrospective observational study: Bevacizumab (B) use and outcomes among metastatic colorectal cancer (mCRC) patients (pts) receiving care in the outpatient community in the United States

Assessment of physician compliance to recommended liver function test monitoring guidelines for patients treated with lapatinib

Utilization of pegfilgrastim in adjuvant chemotherapy regimens for breast cancer in the community

Evaluating utilization characteristics for the Oncotype DX recurrence score in early-stage breast cancer

Understanding male breast cancer in the community setting

Demographic and treatment characteristics for advanced basal cell carcinoma (aBCC) in an oncology outpatient setting

Evaluation of relation between Oncotype DX recurrence score and adjuvant chemotherapy administration

Bevacizumab therapy in advanced non-small cell lung cancer (NSCLC): Outcomes from a community oncology network

Utilization and relative value of breast cancer adjuvant chemotherapy regimens in the community

Treatment patterns in patients with HER2-positive early-stage breast cancer (ESBC) receiving adjuvant treatment with a trastuzumab-containing regimen

Patterns of care and patient characteristics in postmenopausal women with HER2+ and hormone receptor-positive (HR+) metastatic breast cancer (MBC)

Demographics, treatment patterns, safety, and real-world effectiveness in patients ≥70 years of age with chronic lymphocytic leukemia receiving bendamustine with or without rituximab

Bevacizumab (BV) treatment (Tx) to progression (BTP): outcomes from a US community practice network

Impact of comorbidities on clinical and economic outcomes among patients with advanced non-small cell lung cancer (NSCLC) receiving care in the community-based outpatient setting

Observational study evaluating resource utilization among metastatic renal cell carcinoma patients treated with mTOR inhibitors in the outpatient community-based setting

First-line patterns of care and outcomes of HER2-positive breast cancer patients who progressed after receiving adjuvant trastuzumab in the outpatient community setting

Combination versus sequential chemotherapy for metastatic breast cancer: An evaluation of outcomes from a community oncology network

Economic impact of disease progression in follicular non-Hodgkin lymphoma

Economic impact of disease progression in follicular non-hodgkin's lymphoma

Variability of flow cytometry screening for paroxysmal nocturnal hemoglobinuria in five community based oncology practices

First-line trastuzumab utilization: Patterns of care and progression in the community setting

Cost analysis of immunoglobulin prophylaxis in lymphocytic leukemia